Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q00597
UPID:
FANCC_HUMAN
Alternative names:
-
Alternative UPACC:
Q00597; B1ALR8
Background:
The Fanconi anemia group C protein plays a crucial role in DNA repair, particularly in postreplication repair or cell cycle checkpoint functions. It is key in interstrand DNA cross-link repair and maintaining chromosome stability. Additionally, it aids in STAT1 activation upon IFNG induction by facilitating its recruitment to IFNGR1.
Therapeutic significance:
Given its pivotal role in DNA repair and chromosome stability, the Fanconi anemia group C protein is directly linked to Fanconi anemia complementation group C, a disorder marked by bone marrow failure, congenital abnormalities, and cancer predisposition. Targeting this protein could lead to innovative treatments for this complex condition.